Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. MicroTech Medical (Hangzhou) Co's annualized net income for the quarter that ended in Dec. 2025 was HK$93.8 Mil. MicroTech Medical (Hangzhou) Co's average shareholder tangible equity for the quarter that ended in Dec. 2025 was HK$2,155.3 Mil. Therefore, MicroTech Medical (Hangzhou) Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 4.35%.
The historical rank and industry rank for MicroTech Medical (Hangzhou) Co's Return-on-Tangible-Equity or its related term are showing as below:
HKSE:02235'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -39.18 Med: -3.29 Max: 2.09
Current: 2.09
During the past 7 years, MicroTech Medical (Hangzhou) Co's highest Return-on-Tangible-Equity was 2.09%. The lowest was -39.18%. And the median was -3.29%.
HKSE:02235's Return-on-Tangible-Equity is ranked worse than 55.88% of 757
companies
in the Medical Devices & Instruments industry
Industry Median: 4.41
vs HKSE:02235: 2.09
MicroTech Medical (Hangzhou) Co (HKSE:02235) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
MicroTech Medical (Hangzhou) Co Return-on-Tangible-Equity Related Terms
MicroTech Medical (Hangzhou) Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MicroTech Medical (Hangzhou) Co Return-on-Tangible-Equity Chart
HKSE:02235 vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, MicroTech Medical (Hangzhou) Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MicroTech Medical (Hangzhou) Co Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MicroTech Medical (Hangzhou) Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where MicroTech Medical (Hangzhou) Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 4.35% mean?
MicroTech Medical (Hangzhou) Co (HKSE:02235) has a Return-on-Tangible-Equity of 4.35% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on MicroTech Medical (Hangzhou) Co and its competitors. According to the industry distribution chart, MicroTech Medical (Hangzhou) Co ranks #423 out of 757 companies in the Medical Devices & Instruments industry, placing it in the top 55.9%.
Is MicroTech Medical (Hangzhou) Co's Return-on-Tangible-Equity too high?
MicroTech Medical (Hangzhou) Co's current Return-on-Tangible-Equity is 4.35%. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.41. MicroTech Medical (Hangzhou) Co's value of 4.35% is 1.4% below this industry median. Based on the distribution chart, MicroTech Medical (Hangzhou) Co ranks #423 out of 757 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, MicroTech Medical (Hangzhou) Co has a GF Score™ of 80/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MicroTech Medical (Hangzhou) Co's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MicroTech Medical (Hangzhou) Co ranks #423 out of 757 companies for Return-on-Tangible-Equity. This places MicroTech Medical (Hangzhou) Co in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.41. MicroTech Medical (Hangzhou) Co's value of 4.35% is 1.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.41, based on 757 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MicroTech Medical (Hangzhou) Co's current Return-on-Tangible-Equity of 4.35% is 1.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on MicroTech Medical (Hangzhou) Co and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MicroTech Medical (Hangzhou) Co's current Return-on-Tangible-Equity is 4.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MicroTech Medical (Hangzhou) Co stock overvalued right now?
Based on GuruFocus' analysis, MicroTech Medical (Hangzhou) Co (HKSE:02235) is currently considered Possible Value Trap. The stock's GF Value™ is HK$15.94, compared to a current price of HK$7.26 — trading 54.5% below its estimated fair value. The current Return-on-Tangible-Equity is 4.35% and 1.4% below the Medical Devices & Instruments industry median of 4.41. MicroTech Medical (Hangzhou) Co's overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For MicroTech Medical (Hangzhou) Co (HKSE:02235), the current Return-on-Tangible-Equity is 4.35% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MicroTech Medical (Hangzhou) Co (HKSE:02235) Overvalued in 2026?
Based on GuruFocus' analysis, MicroTech Medical (Hangzhou) Co stock appears to be undervalued.
The current stock price of HK$7.26 is trading 54.5% below its estimated GF Value™ of HK$15.94.
GuruFocus considers MicroTech Medical (Hangzhou) Co to be Possible Value Trap.
Key valuation signals for HKSE:02235:
Return-on-Tangible-Equity: 4.35%
GF Value™: HK$15.94 vs. price of HK$7.26 (54.5% below fair value)
Industry Position: 1.4% below the Medical Devices & Instruments median (#423 of 757)
No single metric tells the full story. See the HKSE:02235 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MicroTech Medical (Hangzhou) Co Ltd is focused on diabetes management, providing both diabetes treatment and diabetes monitoring medical devices to improve the diabetes management in China and globally. The Group operates in a large and fast-growing diabetes monitoring, treatment and management market in China and globally with unmet clinical needs. The company derives a majority of its revenue from China.
80GF Score
Get the complete analysis for HKSE:02235
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02235 has been successfully added to your 
